SK Biopharm to Present Cenobamate Research on Generalized Seizures at American Epilepsy Society Meeting

Presentation of 10 Latest Research Findings on Cenobamate

SK Biopharm's U.S. subsidiary, SK Life Science, will present a total of 10 posters, including research on cenobamate for primary generalized tonic-clonic (PGTC) seizures, at the 2025 American Epilepsy Society (AES) Annual Meeting to be held in Atlanta, Georgia, from December 5 to 9, 2025 (local time).

SK Biopharm

At this conference, various research findings on cenobamate, including its clinical efficacy, safety, pharmacokinetics (PK), and real-world data (RWD), will be released. In particular, a Phase 3 clinical study targeting adolescent and adult PGTC patients has been selected as a Late-Breaking Abstract (LBA) and will be presented. This is based on the topline results for generalized seizures that SK Biopharm released in September, and is considered key clinical evidence supporting cenobamate's potential as a broad-spectrum anti-seizure medication.

Additionally, clinical results for a new oral suspension formulation of cenobamate, which is currently only available as an oral tablet, will also be presented. The study confirmed that the relative bioavailability between the tablet and oral suspension formulations is similar, and that administration is possible regardless of food intake. Based on these results, the company plans to submit a New Drug Application (NDA) for the oral suspension formulation within this year.

A symposium titled "Illuminating New Pathways to Seizure Reduction" will also be held. This session will highlight the evolution of treatment for drug-resistant epilepsy and the role of third-generation anti-seizure medications, and will discuss how treatment choices impact patient outcomes through real-world patient journeys. In addition, there will be discussions on recent changes in physician perceptions and treatment approaches aimed at achieving complete seizure freedom.

Sunita Misra, Executive Vice President of Global Clinical Development and Medical Affairs at SK Life Science, stated, "AES 2025 is an opportunity to clinically confirm cenobamate's potential for treating generalized seizures and to explore innovative directions in epilepsy treatment with global experts." She added, "Through new clinical data on cenobamate, we aim to offer both healthcare professionals and patients the possibility of new treatment options."

This content was produced with the assistance of AI translation services.